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Abstract
Background: Axial spondyloarthritis (axSpA) is a disabling inflammatory joint disease with chronic low back pain
(CLBP) as leading symptom. Recognizing axSpA in the large amount of CLBP patients is difficult for general
practioners (GP). This evaluation aims to assess the effect of a referral strategy for axSpA in young primary care
patients with CLBP by comparing the use of the strategy with usual care. The effect is measured at three different
levels; by patient reported outcomes (the clinical effect), process and costs evaluation.
Methods/Design: This study design is a cluster randomized controlled trial with GP as clusters. GPs throughout the
Netherlands are invited to participate and randomized to either the intervention or the control group. Patients from
participating GPs are invited to participate if they have ever been registered with low back pain, without radiation
(ICPC L03) and aged 18–45 years. To be included in the study, patients need to have current low back pain and
chronic low back pain (>12 weeks). In the intervention arm a referral strategy for axSpA will be applied in CLBP
patients, in the control arm care as usual will be provided for CLBP patients. The referral strategy consists of four
easy to use variables. All are questions about the back pain complaints of the patients. Data is prospectively
collected in an online database at baseline (T0), 4 months (T1), 12 months (T2) and 24 months (T3). After time point
T1 (4 months) patients from the control group will also receive the intervention i.e. the application of a referral
strategy for axSpA. The effect of the referral strategy is measured at three different levels, by patient outcomes (e.g.
pain scores, quality of life), process measures (e.g. number of axSpA diagnoses by rheumatologists) and by costs
(work productivity and health care resources use). Our primary outcome is the Roland Morris Disability
Questionnaire after 4 months, secondary outcomes are pain and quality of life. Costs will be assessed before and
after the use of the referral strategy, to estimate if the use of the strategy will lead to a reduction in health care
costs and improvement in work participation.
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Discussion: It is anticipated that using the axSpA referral strategy for primary care CLBP patients will increase the
quality of life of CLBP patients, will result in more (correct) diagnoses of axSpA by the rheumatologists, and will be
cost-effective. Ultimately, the results of this study may contribute to the startup of a national implementation of the
axSpA referral strategy to identify timely CLBP patients with axSpA.
Trial registration: NCT01944163, date of registration; September 6, 2013 (Clinicaltrials.gov)
Keywords: Axial Spondyloarthritis, Chronic Low Back Pain, Primary Care, Referral, Cost-effectiveness, Cluster
Randomized Trial
Background
Low back pain (LBP) is one of the most common
musculoskeletal disorders affecting up to 85 % of the
adults at some point in their lives [1]. In 10–28 % of
the patients the pain persists for more than 12 weeks
and becomes chronic [2]. On top of the high preva-
lence, LBP is the leading cause of years lived with
disability (YLD). The YLD of low back pain is higher
than the YLD of e.g. major depressive disorders,
anemia, chronic obstructive pulmonary disease and
diabetes [3].
One of the possible causes of chronic low back pain
(CLBP) is axial spondyloarthritis (axSpA) which is a het-
erogeneous inflammatory joint disease. Two recent stud-
ies showed a prevalence of axSpA among young (18–45
years) CLBP patients between 16 % and 24 % [4, 5]. Re-
cently the focus of axSpA is on early diagnosis consider-
ing treatment is more effective in patients with short
symptom duration [6]. For an early diagnosis of axSpA
by rheumatologists, early recognition in primary care is
important. However recognition of axSpA is difficult be-
cause specific signs or symptoms do not exist [7]. More-
over, in the current CLBP guidelines for GPs no referral
guidelines for axSpA are included [8].
Within the field of rheumatology several models to
identify patients at high risk for axSpA have been pub-
lished, these models combine multiple predictors, such
as clinical symptoms, patients’ characteristics and test
results to estimate the probability of the disease. Almost
all published referral models are tested in a pre-selected
population with a high prior probability of axSpA. Only
one referral strategy is developed and externally vali-
dated in a primary care CLBP population, the CaFaSpA
referral rule [4, 5]. This low cost referral rule is easy to
use and consists of four variables, all variables are ques-
tions. The GP can ask these questions while taking a pa-
tient’s history.
After development and external validation of a referral
rule the next step before application in daily practice is
to investigate the impact of the referral rule [9, 10].
Since the CaFaSpA referral rule can identify axSpA pa-
tients, it is worthwhile to perform an impact analysis to
determine its effect in primary care.
Objective of the evaluation
This study entails a clinical effect, process and cost evalu-
ation of using the axSpA referral strategy for primary care
CLBP patients. The study aims to determine to what ex-
tent use of the rule, in comparison with usual care, leads
to less disability and pain and improved quality of life in
CLBP patients. Second, it evaluates if the referral strategy
leads to more diagnosis of axSpA and finally health care
costs and work participation will be compared before and
after the application of the referral strategy.
Methods
Design
The study uses a cluster randomized controlled trial de-
sign which is carried out in the primary care setting in
the Netherlands. Sixty primary care practices will be ran-
domized to either the intervention or the control (usual
care) group. Each cluster contains the GPs from one
practice and their included patients.
General practices
GPs at the surrounding areas of participating Dutch rheu-
matologists will be invited to participate by an invitation
letter. Two weeks after this invitation letter a member our
research team will call the GP to assure if the GP was in-
terested in participating. The only exclusion criteria for
GPs is not using the International Classification of Pri-
mary Care (ICPC) coding system for their patients, as pa-
tients will be selected from the GP practice using the
ICPC system. The ICPC is the standard for coding and
classification of signs, symptoms and complaints in gen-
eral practice. The Dutch ICPC is managed and maintained
by the Netherlands Society of General Medical Practi-
tioners (NHG). At present, most general practice informa-
tion systems use the ICPC codes.
Recruitment of patients and eligibility criteria
Patients will be recruited from participating practices by
searching their records for patients with ICPC L03 and
aged between 18 and 45 years. The recruitment of
patients is the same for GPs randomized to the interven-
tion as for GPs randomized to the control group. All se-
lected patients will receive a letter from their GP briefly
van Hoeven et al. BMC Musculoskeletal Disorders  (2016) 17:278 Page 2 of 7
explaining the study and asking the patient to respond
using the attached return form. If the patient does not
respond to the invitation within 4 weeks, a second invi-
tation letter will be sent.
The inclusion criteria are:
– Age 18–45 years
– Ever registered with low back pain, without
radiation ICPC L03
– Current low back pain
– ≥12 weeks low back pain
The exclusion criteria are:
– A clear explanation for the back pain (like a trauma,
hernia nuclei pulposi or malignancy)
– Mentally incompetent (inability of a person to make
or carry out important decisions regarding his or
her affairs)
– No understanding of the Dutch language (written)
Patients who agree to participate sign a consent form,
thereafter they will be called by a research assistant to
confirm the inclusion criteria. The research assistant will
register the answers to the CaFaSpA referral rule of the
participant. After this telephone contact the patient will
receive online questionnaires per email concerning their
back pain. If email contact it is not possible, the patient
will receive the questionnaires by post.
Those who do not wish to participate will be registered
by gender, date of birth and the reason for not participat-
ing, such as no current low back pain, no time, etc.
Randomisation, allocation procedure and blinding
Primary care practices are randomly allocated to either
the intervention or the control group. Randomisation is
stratified for number of GPs working in the primary care
practice (one or two vs more than two) to ensure similar
number of patients in both groups. The block random-
isation schedule is computer generated and adminis-
trated by an independent person, who is not involved in
patient care. It is impossible to blind patients or GPs for
allocation. If a patient receives the advice of a referral to
the rheumatologist, both the patient and the GP are ac-
tively involved in this referral. Also the outcome assess-
ment is not blinded, as patients assess the outcomes
themselves by filling in questionnaires. Blinded analyses
of the data will take place when possible.
Intervention
The intervention is the application of the CaFaSpA re-
ferral rule by GPs in young primary care patients with
CLBP [4]. [5] (Table 1) The CaFaSpA rule is explained
to GPs, first by phone and thereafter by sending written
materials explaining the referral rule. To ensure that the
intervention is equally applied in all participants, not the
GP but a research assistant registers the answers to the
referral rule from a patient. This takes place in the same
telephone contact in which the inclusion and exclusion
criteria are checked. The outcome of the intervention
i.e. the outcome of the CaFaSpA referral rule is commu-
nicated by a letter to both the GP and the participant. If
the referral rule is positive, a referral to the rheumatolo-
gist will be advised. Thereafter it is the responsibility of
the GP and the patient to arrange a referral to the
rheumatologist.
Control group
Participating patients of the control group are also called
by our research assistant to check the inclusion criteria
and to register the answers to the CaFaSpA referral rule.
No active advice regarding a referral takes place. If control
group patients choose to go to their GP, they will be
treated according to the Dutch College of General Practice
guidelines for the management of low back pain [11].
Before the IMPACT study started we discussed with
GPs the weaknesses and difficulties of our study design.
We received feedback concerning the benefit of partici-
pating for GPs or patients who were randomized to the
control group. It was feared that the lost to follow up
would be great in the usual care group. To increase the
feasibility of our study we decided to communicate the
outcome of the referral rule to the control group after
Table 1 The CaFaspA referral strategy
Applicable in patients ≥3 months back pain and age at oneset <45 years
Inflammatory back pain
Inflammatory back pain is considered present if at least four questions
are answered with yes
-Age at onset<40 years
-Insidious onset
-Improvement with exercise
-No improvement with rest
-Pain at night (with improvement upon getting up)
Positive family history
A positive family history is considered present if there is a first or second
degree family member with axial spondyloarthritis, Crohn’s disease,
psoriasis or uveitis anterior
Good reaction to NSAIDs
A good reaction to NSAIDs is present when a patient reports a relieve in
pain perception within 48 hours after receiving a NSAID
CLBP ≥5 years
A long low back duration is present if the duration of the back pain is 5
years or longer
If at least two out of the four referral parameters are present→ a referral
to the rheumatologist is advised
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4 months and thereby eliminating the contrast between
the intervention and usual care group.
Therefore, four months after inclusion (after our pri-
mary outcome time point) the usual care CLBP patients
and their GPs will receive a letter containing the out-
come of the referral rule and an advice to refer or not
refer the patient. After receiving the outcome of the re-
ferral rule the patients of the control group will be
followed for two years, data will be collected after 1 and
2 years of exposure to the referral rule, this will be six-
teen and twenty-eight months after inclusion of the
study (Fig. 1).
Data collection
Data collection of patient outcomes are at baseline (T0)
(directly after inclusion of a patient in the study), after
4 months (T1), after 12 or 16 months (T3) and after 24
or 28 months (T4) (Fig. 1). At each time point patients
will automatically receive an email with a link to online
questionnaires.
Outcome measures
The primary clinical outcome is the score on the Roland
Morris Disability Questionnaire (RMDQ) after 4 months
[12]. The RMDQ is a patient reported outcome and has
a scale of 0 to 24. A higher score indicates a more severe
disability score. The advantage of using the RMDQ as
primary outcomes measure is that it is applicable in all
participants as all participants are suffering from low
back pain complaints. While for instance the BASDAI is
only validated to use in axSpA patients. In general, the
outcomes measures can be divided into three categories:
– Patient reported outcomes
o Disability measured by the Roland Morris
Disability questionnaire
o Pain measured by the Visual Analogue Scale
(VAS) pain [13]
o Health related quality of life measured by the SF-
36 version 2 and EQ-5D [14, 15].
o Disease activity for axSpA, measured by the
BASDAI [16].
o Neuropathic components related to back pain
measured by the painDETECT [17]
– Process
o Diagnosis of axial spondyloarthritis made by
rheumatologists, which is verified by hospital
records.
– Costs
o Loss of work-productivity measured by work
participation (iMTA Productivity Cost
Questionnaire iPCQ)) [18]
o Health care resources use measured by the iMTA
Medical Consumption Questionnaire [19]
Compliance
The compliance of patients is optimized by sending up
to three reminders emails, asking the patient to fill out
the online questionnaires. If the patient still has not
completed the questionnaires the research assistant will
Fig. 1 Flowchart of the IMPACT study
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contact the patient by telephone and the questionnaires
are sent to the patient by post.
Sample size
For the power calculation we assumed a difference of 2.5
points on the RMDQ at four months between the refer-
ral rule and usual care group. These 2.5 points are the
clinically significant difference, found in previous studies
[20, 21]. The SD of the RMDQ is 6.0 based on data ob-
served in the previous CaFaSpA 2 study [4]. Detection of
this 2.5 point improvement in a randomized trial would
require 180 patients per group, using a two-sided α of
0.05 and power of 0.80.
Patient in the intervention group who have a negative
result of the referral strategy (i.e. no referral to the
rheumatologist) will receive the same treatment as the
usual care group. Therefore, the effect of the referral
strategy can only be assessed in patients with a positive
result of the referral strategy. From the previous
CaFaSpA studies we know that around 50 % of the par-
ticipating patients will have a positive result. Therefore
360 patients(180 x2)would be required for 80 % power.
Further, the sample size was adjusted for cluster
randomization based on an intra-cluster correlation coeffi-
cient of 0.05 and an average cluster size of 16 [22]. [23]
The average cluster size is based on data of the CaFaSpA
1 and 2 studies, with on average 16 participating patients
per GP. With these findings we can calculate the design
effect; design effect = 1 + (16–1) * 0.05 = 1.75
Multiplying 360 patients by the design effect of 1.75 im-
plies that a total of 630 patients must be included in this
study. If a lost to follow up of 25 % is taken into account
840 patients need to be enrolled. Assuming 16 CLBP pa-
tients per GP, implies that 54 GPs (840/16) need to be ran-
domized (Fig. 2). We expect that 16 patient per GP
practice will participate, if the number of participating pa-
tients per practice is smaller, for example only 6, this will
lead to a smaller design effect (1.25) and a total of only
600 patients should be enrolled to create sufficient power.
Data analysis
Effects at 4 months and the process evaluation will be
analysed according to the intention-to-treat principle.
The baseline characteristics of the patients will be sum-
marized by randomisation group, reported as mean
(standard deviation) or median (interquartile range) for
continuous variables and count (percent) for categorical
variables.
As this is a cluster-randomized trial mixed effect re-
gression analysis will be used to compare the mean
RMDQ score after four months between the interven-
tion and usual care group. Fixed effects include alloca-
tion group and result of the referral strategy (referral y/
n). As the effect of the referral strategy is expected in
the subgroup of patient with a referral advice, an inter-
action term between allocation group and result of the
referral strategy will also be included. A random inter-
cept will be included adjusting for clustering [24, 25].
This random intercept stand for the effect of different
primary care practices (i.e. clusters).
For the secondary outcomes we will again use a mixed
effect regression analysis to estimate the effect of the use
of the referral strategy after 4 months on process level (i.e.
the number of axSpA diagnoses by a rheumatologists),
pain (VAS pain), quality of life (SF-36 version 2 and EQ-
5D) and disease activity (BASDAI). We will use linear re-
gression for continuous outcomes and logistic regression
for dichotomous outcomes. Similar to the primary out-
come analysis an interaction term and random intercept
will be used to take into account interaction between allo-
cation group and referral strategy and clustering. We
intended to assess the effect of using the referral strategy
also at 12 and 24 months. However, patients in the con-
trol group receive also an advice based on the referral
rule after 4 months. Contract between the interven-
tion and control group is no longer present. There-
fore, individual trajectories will be modeled using
random effect regression with patient outcome as the
dependent variable and time as covariate and a ran-
dom intercept for patient.
For the cost evaluation we will compare costs before
and after the application of the referral strategy. We will
consider costs of provided health care and costs due to
loss of work-productivity. In order to calculate costs, the
volume of care will be linked to the actual, integrated
cost prices per medical service [26].
A p-value of <0.05 will be considered statistically sig-
nificant. Statistical analyses will be undertaken with
STATA.
Discussion
This evaluation aims to assess the effects on patient out-
comes, processes and costs of a referral strategy for
axSpA in young primary care patients with CLBP by
Fig. 2 Sample size calculation taking clustering into account (ICC of 0.05)
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comparing the use of the strategy with usual care. The
study started in July 2014 and the first results are ex-
pected in May 2016.
There are only a very few impact studies in the field of
prognostic research. In a recent review there were 61 de-
velopment studies and only 2 (3 %) of them also had an
impact evaluation [27], an essential step to asses clinical
effectiveness and costs.
The main strength of this study is that it provides infor-
mation on the process outcome (referral to the rheuma-
tologists and result of the diagnostic process) and on the
patient outcomes (pain and quality of life). The combin-
ation of process and patients outcomes allows for a better
interpretation of findings. An effect in process does not
necessarily results in improved patient outcomes. Possible
absence of effect in patient outcomes, on the other hand,
may be the result of insufficient improvement in the
process. Further, the study measures the impact of a vali-
dated referral strategy. The referral strategy has already
shown to discriminating axSpA patients from other CLBP
patients [4]. We have chosen to only test the impact of the
CaFaSpA referral strategy as this is the cheapest and the
most feasible strategy for primary care of all proposed re-
ferral strategies for axSpA.
A weakness of the study is that the contrast between
intervention and control groups disappears after 4 months,
as patients of the control group are also provided with the
advice of the referral strategy. Nevertheless our primary
outcome is assessed before the contract between interven-
tion and control group is eliminated. We expect that
4 months is a sufficient period to achieve a substantial im-
provement in the primary outcome by using the referral
strategy in the intervention group. For other outcomes we
can use a before after design within patients which is ac-
ceptable as the back pain complaints are chronic. Another
potential weakness is that patients are selected by a regis-
try, rather than only actively care seeking patients are in-
vited to participate. This can lead to a lower participation
rate of the invited patients and a potential selection bias of
only severe cases of low back pain. However in the prior
CaFaSpA studies, the same approach to select participants
by the GP register was conducted and this didn’t result in
a more severe low back pain study population [4, 5]. In
both CaFaSpA studies was the VAS pain comparable with
other low back pain cohorts. One last limitation of this
study is that the intervention i.e. the CaFaSpA referral rule
is applied by research assistant not by GPs themselves, this
pragmatic approach can influence the outcomes of the
study. We have chosen for this pragmatic approach as
GPs pointed before the start of study that it is often too
busy during consultation hour to properly ask the ques-
tions of the referral rule and that the application of the re-
ferral rule would not be uniform but heavenly time
dependent.
If this study succeeds in demonstrating an impact of
applying the referral strategy for axSpA in young CLBP
patients, the potential benefit may be substantial. The
care provided to CLBP patients can be improved, it will
be easier for GPs to refer the CLBP patient with a high
risk for axSpA to the rheumatologist. And an earlier diag-
nosis of axSpA has favorable outcomes, as several studies
have shown that an effective treatment in axSpA patients
results in a lower disease activity, improved quality of life
and enhanced work participation [28, 29]. And finally the
gain for society; CLBP is a great socio-economic burden for
society. When one of the causes for CLBP is recognized
earlier and subsequently diagnosed and treated in an earlier
stage this can lead to decreased sick leave due to back pain
and increased work productivity.
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